HRP960014A2 - New applications of lysozyme dimer - Google Patents
New applications of lysozyme dimer Download PDFInfo
- Publication number
- HRP960014A2 HRP960014A2 HR95110638.4A HRP960014A HRP960014A2 HR P960014 A2 HRP960014 A2 HR P960014A2 HR P960014 A HRP960014 A HR P960014A HR P960014 A2 HRP960014 A2 HR P960014A2
- Authority
- HR
- Croatia
- Prior art keywords
- lysozyme
- lysozyme dimer
- preparation
- klp
- dimer
- Prior art date
Links
- 102000016943 Muramidase Human genes 0.000 title claims description 92
- 108010014251 Muramidase Proteins 0.000 title claims description 92
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 title claims description 92
- 229960000274 lysozyme Drugs 0.000 title claims description 92
- 235000010335 lysozyme Nutrition 0.000 title claims description 92
- 239000004325 lysozyme Substances 0.000 title claims description 92
- 239000000539 dimer Substances 0.000 title claims description 78
- 238000011282 treatment Methods 0.000 claims description 46
- 238000002360 preparation method Methods 0.000 claims description 40
- 235000019688 fish Nutrition 0.000 claims description 31
- 241000251468 Actinopterygii Species 0.000 claims description 29
- 230000003779 hair growth Effects 0.000 claims description 28
- 241001465754 Metazoa Species 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 22
- 208000004631 alopecia areata Diseases 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 15
- 239000000178 monomer Substances 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 8
- 230000003449 preventive effect Effects 0.000 claims description 8
- 230000000638 stimulation Effects 0.000 claims description 8
- 241000282412 Homo Species 0.000 claims description 7
- 241000710921 Infectious pancreatic necrosis virus Species 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 210000000987 immune system Anatomy 0.000 claims description 7
- 230000007246 mechanism Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 6
- 239000006227 byproduct Substances 0.000 claims description 6
- 208000010824 fish disease Diseases 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 208000037824 growth disorder Diseases 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 206010017553 Furuncle Diseases 0.000 claims description 3
- 208000003512 furunculosis Diseases 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000013589 supplement Substances 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 241000972773 Aulopiformes Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 claims description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims description 2
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 235000013601 eggs Nutrition 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 238000010353 genetic engineering Methods 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000001172 regenerating effect Effects 0.000 claims description 2
- 235000019515 salmon Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 241001327682 Oncorhynchus mykiss irideus Species 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 239000003814 drug Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 11
- 210000004209 hair Anatomy 0.000 description 11
- 210000004761 scalp Anatomy 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 230000000242 pagocytic effect Effects 0.000 description 10
- 210000001541 thymus gland Anatomy 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 241000257303 Hymenoptera Species 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 230000008260 defense mechanism Effects 0.000 description 8
- 210000001165 lymph node Anatomy 0.000 description 8
- 238000011640 AKR mouse Methods 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 201000004384 Alopecia Diseases 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000003659 hair regrowth Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 229960003632 minoxidil Drugs 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 208000022362 bacterial infectious disease Diseases 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 102000003896 Myeloperoxidases Human genes 0.000 description 4
- 108090000235 Myeloperoxidases Proteins 0.000 description 4
- 241000277275 Oncorhynchus mykiss Species 0.000 description 4
- 231100000360 alopecia Toxicity 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000009372 pisciculture Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 108010075016 Ceruloplasmin Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 3
- 244000062730 Melissa officinalis Species 0.000 description 3
- 235000010654 Melissa officinalis Nutrition 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000009341 apiculture Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007124 immune defense Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000000865 liniment Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 208000003747 lymphoid leukemia Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 241000607525 Aeromonas salmonicida Species 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000701931 Canine parvovirus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 210000002816 gill Anatomy 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000003660 reticulum Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000003797 telogen phase Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 206010001766 Alopecia totalis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000277334 Oncorhynchus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 108010065081 Phosphorylase b Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000030695 Sparse hair Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001420 bacteriolytic effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002895 hyperchromatic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000004176 reticulum cell Anatomy 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Fish Paste Products (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95100446 | 1995-01-13 | ||
| EP95110638 | 1995-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP960014A2 true HRP960014A2 (en) | 1997-12-31 |
Family
ID=26138401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR95110638.4A HRP960014A2 (en) | 1995-01-13 | 1996-01-12 | New applications of lysozyme dimer |
Country Status (37)
| Country | Link |
|---|---|
| EP (2) | EP0804227B1 (cs) |
| JP (1) | JPH10511974A (cs) |
| KR (1) | KR100420377B1 (cs) |
| CN (1) | CN1090506C (cs) |
| AP (2) | AP628A (cs) |
| AT (1) | ATE218367T1 (cs) |
| AU (1) | AU709620B2 (cs) |
| BA (1) | BA96074A (cs) |
| BG (1) | BG62239B1 (cs) |
| BR (1) | BR9606973A (cs) |
| CA (1) | CA2210091A1 (cs) |
| CZ (1) | CZ293353B6 (cs) |
| DE (2) | DE804227T1 (cs) |
| DZ (1) | DZ1964A1 (cs) |
| EA (1) | EA001462B1 (cs) |
| EE (1) | EE9700154A (cs) |
| ES (1) | ES2109208T1 (cs) |
| FI (1) | FI972943L (cs) |
| GB (1) | GB2311724B (cs) |
| GE (1) | GEP20012571B (cs) |
| GR (1) | GR970300047T1 (cs) |
| HR (1) | HRP960014A2 (cs) |
| HU (1) | HU223903B1 (cs) |
| IL (1) | IL116737A (cs) |
| MA (1) | MA23775A1 (cs) |
| MD (1) | MD1633C2 (cs) |
| MY (1) | MY132437A (cs) |
| NO (1) | NO973203D0 (cs) |
| NZ (1) | NZ298432A (cs) |
| OA (1) | OA10436A (cs) |
| PL (1) | PL185678B1 (cs) |
| SK (1) | SK94297A3 (cs) |
| SV (1) | SV1996000001A (cs) |
| TN (1) | TNSN96004A1 (cs) |
| TR (1) | TR199700633T1 (cs) |
| UA (1) | UA50728C2 (cs) |
| WO (1) | WO1996021463A2 (cs) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6123937A (en) * | 1997-03-14 | 2000-09-26 | Nika Health Products, Limited | Applications of lysozyme dimer |
| ATE211389T1 (de) * | 1998-04-27 | 2002-01-15 | Nika Health Products Ltd | Zusammensetzung zur verbesserung der fruchtbarkeit und ihre verwendung |
| AUPP489798A0 (en) * | 1998-07-28 | 1998-08-20 | Mediko Pty Ltd | Hair growth/maintenance compositions and methods |
| CA2679939A1 (en) * | 2007-03-02 | 2008-09-12 | Stefano Ferrari | Composition and method for treating papilloma virus and equine sarcoids |
| CN103518978B (zh) * | 2013-10-22 | 2016-01-13 | 上海艾魁英生物科技有限公司 | 新型溶菌酶制剂及其制备方法 |
| CN111643655A (zh) * | 2013-12-18 | 2020-09-11 | 帝斯曼知识产权资产管理有限公司 | 用于含角蛋白的组织的包含溶菌酶水解物的组合物 |
| CN104585546B (zh) * | 2015-01-20 | 2019-02-05 | 上海海洋大学 | 一种促生长抗应激罗非鱼饲料及其制备方法 |
| CN105707509B (zh) * | 2016-01-25 | 2018-12-28 | 浙江艾杰斯生物科技有限公司 | 一种用于防治草鱼烂腮病的饲料添加剂 |
| WO2020099556A1 (en) | 2018-11-14 | 2020-05-22 | Universiteit Antwerpen | Oxidized lysozyme |
| US20220273733A1 (en) * | 2019-07-26 | 2022-09-01 | Evolve Biosystems, Inc. | Nutritive compositions with bioactive proteins |
| CN111657407A (zh) * | 2020-05-14 | 2020-09-15 | 上海艾魁英生物科技有限公司 | 提高断奶仔猪非特异性免疫功能的饲料添加剂、其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5533408A (en) * | 1978-08-30 | 1980-03-08 | Eisai Co Ltd | Immunity-increasing agent |
| JPS5543040A (en) * | 1978-09-25 | 1980-03-26 | Eisai Co Ltd | Immunity raising agent |
| DE3230999A1 (de) * | 1982-08-20 | 1984-02-23 | Philips Kommunikations Industrie AG, 8500 Nürnberg | Verfahren zur zugriffssteuerung bei einem nachrichtensystem |
| JPS61158793A (ja) * | 1984-11-14 | 1986-07-18 | Takeda Chem Ind Ltd | ヒト・リゾチ−ムの合成遺伝子 |
| RU2061496C1 (ru) * | 1985-08-02 | 1996-06-10 | Институт общей патологии и экологии человека | Средство, стимулирующее эритропоэз |
| AU1366088A (en) * | 1987-01-28 | 1988-08-24 | Ortho Pharmaceutical Corporation | Immunosuppressive peptides and methods of use |
| AU624331B2 (en) * | 1988-05-26 | 1992-06-11 | Nika Health Products Ltd. | A composition having as its active ingredient lysozyme or ribonuclease dimer in a pharmaceutically acceptable carrier |
| KR0158216B1 (ko) * | 1990-01-08 | 1998-11-16 | 카를하인츠 리터 | 제약학적 조성물에 사용할 수 있는 리소자임 이량체를 만드는 개량된 방법 |
| BR9007970A (pt) * | 1990-01-08 | 1992-11-17 | Nika Health Products Ltd | Processo para preparacao de dimeros de ribonuclease |
| PL173978B1 (pl) * | 1992-07-13 | 1998-05-29 | Nika Health Products Ltd | Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej |
| RU2082413C1 (ru) * | 1993-06-30 | 1997-06-27 | Нижегородский государственный медицинский институт | Способ лечения язвенной болезни двенадцатиперстной кишки |
| RU2071339C1 (ru) * | 1994-07-25 | 1997-01-10 | Щербакова Элеонора Григорьевна | Средство для лечения и профилактики дисбактериоза |
| RU2123345C1 (ru) * | 1997-07-31 | 1998-12-20 | Научно-исследовательский институт детского питания Российской Академии сельскохозяйственных наук | Средство для лечения дисбактериоза |
-
1996
- 1996-01-10 DZ DZ960005A patent/DZ1964A1/fr active
- 1996-01-11 IL IL11673796A patent/IL116737A/xx not_active IP Right Cessation
- 1996-01-11 TN TNTNSN96004A patent/TNSN96004A1/fr unknown
- 1996-01-12 SV SV1996000001A patent/SV1996000001A/es unknown
- 1996-01-12 MY MYPI96000118A patent/MY132437A/en unknown
- 1996-01-12 HR HR95110638.4A patent/HRP960014A2/hr not_active Application Discontinuation
- 1996-01-12 BA BA960074A patent/BA96074A/bs unknown
- 1996-01-12 AP APAP/P/1996/000783A patent/AP628A/en active
- 1996-01-13 EE EE9700154A patent/EE9700154A/xx unknown
- 1996-01-13 TR TR97/00633T patent/TR199700633T1/xx unknown
- 1996-01-13 AT AT96900321T patent/ATE218367T1/de not_active IP Right Cessation
- 1996-01-13 GE GEAP19963815A patent/GEP20012571B/en unknown
- 1996-01-13 CZ CZ19972202A patent/CZ293353B6/cs not_active IP Right Cessation
- 1996-01-13 WO PCT/EP1996/000135 patent/WO1996021463A2/en not_active Ceased
- 1996-01-13 PL PL96321546A patent/PL185678B1/pl not_active IP Right Cessation
- 1996-01-13 EA EA199700101A patent/EA001462B1/ru not_active IP Right Cessation
- 1996-01-13 FI FI972943A patent/FI972943L/fi unknown
- 1996-01-13 KR KR1019970704726A patent/KR100420377B1/ko not_active Expired - Fee Related
- 1996-01-13 CA CA002210091A patent/CA2210091A1/en not_active Abandoned
- 1996-01-13 SK SK942-97A patent/SK94297A3/sk unknown
- 1996-01-13 NZ NZ298432A patent/NZ298432A/en unknown
- 1996-01-13 HU HU9801689A patent/HU223903B1/hu not_active IP Right Cessation
- 1996-01-13 GB GB9714354A patent/GB2311724B/en not_active Expired - Fee Related
- 1996-01-13 MD MD97-0244A patent/MD1633C2/ro unknown
- 1996-01-13 BR BR9606973A patent/BR9606973A/pt not_active Application Discontinuation
- 1996-01-13 AP APAP/P/1997/001024A patent/AP871A/en active
- 1996-01-13 UA UA97063430A patent/UA50728C2/uk unknown
- 1996-01-13 JP JP8521448A patent/JPH10511974A/ja active Pending
- 1996-01-13 EP EP96900321A patent/EP0804227B1/en not_active Expired - Lifetime
- 1996-01-13 AU AU43916/96A patent/AU709620B2/en not_active Ceased
- 1996-01-13 ES ES96900321T patent/ES2109208T1/es active Pending
- 1996-01-13 EP EP00124590A patent/EP1086703A3/en not_active Withdrawn
- 1996-01-13 CN CN96192331A patent/CN1090506C/zh not_active Expired - Fee Related
- 1996-01-13 DE DE0804227T patent/DE804227T1/de active Pending
- 1996-01-13 DE DE69621589T patent/DE69621589D1/de not_active Expired - Lifetime
- 1996-01-15 MA MA24130A patent/MA23775A1/fr unknown
-
1997
- 1997-06-30 BG BG101709A patent/BG62239B1/bg unknown
- 1997-07-10 NO NO973203A patent/NO973203D0/no not_active Application Discontinuation
- 1997-07-11 OA OA70048A patent/OA10436A/en unknown
- 1997-12-31 GR GR970300047T patent/GR970300047T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kohchi et al. | Applications of lipopolysaccharide derived from Pantoea agglomerans (IP-PA1) for health care based on macrophage network theory | |
| RS49831B (sr) | Farmaceutske kompozicije tizoksanida i nitazoksanida | |
| HRP960014A2 (en) | New applications of lysozyme dimer | |
| JPH11504000A (ja) | 造血前駆細胞の増殖を促進するチオール類 | |
| US6183742B1 (en) | Applications of lysozyme dimer | |
| RU2647455C1 (ru) | Композиция, обладающая иммуностимулирующим действием для сублингвального применения | |
| JP5291290B2 (ja) | 化学療法を受けている癌患者の治療方法 | |
| WO2002074311A1 (en) | Antitumoral, antiviral, antibacterial, antiparasitic, anti-inflammatory, immunomodulatory and antimicotic medicinal preparation, method for production and dosage forms thereof | |
| JPH07508010A (ja) | ＤＮＡウイルス感染の治療のための薬物の製造のための膜翅類昆虫（ｈｙｍｅｎｏｐｔｅｒａ）毒の使用 | |
| RU2105504C1 (ru) | Пищевая биологически активная добавка "тинростим-с" | |
| US9308243B2 (en) | Cellular enhancements in biological systems through the use of li-pofullerene and peptide group combinations | |
| RU2378011C1 (ru) | Способ профилактики бруцеллеза крупного рогатого скота | |
| US20020098171A1 (en) | New application of lysozyme dimer | |
| RU2136303C1 (ru) | Способ получения средства для лечения ларвального и стробилярного эхинококкозов "чеблин ск-1" | |
| MXPA97005246A (en) | New applications of dimero de lisoz | |
| RU2414223C1 (ru) | Средство, обладающее иммуностимулирующим и гемостимулирующим действием | |
| Aswad et al. | Formulation and Evaluation of Snakehead Fish Mucus Emulgel for Enhanced Wound Healing and Antibacterial Activity | |
| RU2329791C2 (ru) | Способ стимуляции гемопоэза при лечении острой лучевой болезни у собак | |
| WO2005042015A1 (en) | Pharmaceutical anti-herpetic composition, method for producing a dosage form based thereon and method for the use thereof | |
| Turky et al. | ASSESSMENT STUDY FOR THE ACTIVITY OF SPECIFIC ALGAL EXTRACTS IN THE TREATMENT OF CUTANEOUS LEISHMANIASIS IN MAYSAN GOVERNORATE | |
| RU2246965C1 (ru) | Средство для лечения токсоплазмоза | |
| RU2568869C1 (ru) | Способ лечения демодекоза собак | |
| SU1651905A1 (ru) | Способ лечени дикроцелиоза овец | |
| WO2009042708A1 (en) | Regeneration anti-inflammatory composition and method for treating a retinal dystrophy using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20020112 Year of fee payment: 7 |
|
| ODBI | Application refused |